Abstract:This study examined the impact of hormone replacement therapy (HRT) on the occurrence of various cancers in postmenopausal women with de novo or a history of endometriosis. In the datasets for ten cancers (cervical, uterine, ovarian, breast, colon, gastric, liver, lung, pancreatic, and thyroid), women who received HRT (the HRT group) and those who did not (the control group) were selected by a 1:1 matching with those who met the study criteria. In the dataset for each cancer, the incidence of each cancer was very low (0.2% to 1.5% in the HRT group and 0.2% to 1.3% in the control group). The duration of HRT was 1.3 ± 2.1 years. After adjusting for co-variables, HRT was a significant risk factor for uterine cancer (p < 0.05). However, the risk of liver cancer decreased significantly with duration of HRT (p < 0.05). Moreover, combined estrogen and progesterone decreased the risks of liver and thyroid cancers significantly (p < 0.05), and estrogen alone decreased the risks of breast and lung cancers significantly (p < 0.05). Tibolone was not associated with the risk of any of the cancers assessed. These results can help guide the use of HRT in women with de novo or a history of endometriosis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the impact of hormone replacement therapy (HRT) on the risk of various cancers in post - menopausal women with new - onset or a history of endometriosis. Specifically, the researchers hope to understand whether HRT will affect the risk of these women developing cervical cancer, uterine cancer, ovarian cancer, breast cancer, colon cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer and thyroid cancer. ### Main research questions: 1. **The impact of HRT on cancer risk**: Does HRT increase or decrease the risk of these women developing the above ten cancers? 2. **The impact of different types of HRT on cancer risk**: What are the different impacts of using estrogen alone, using estrogen and progesterone in combination, and using tibolone on cancer risk? 3. **The impact of the duration of HRT on cancer risk**: Does the length of time of using HRT affect cancer risk? ### Research background: - **Endometriosis**: This is a chronic, recurrent benign disease, which mainly occurs in the pelvic cavity, but can also appear in areas far away from gynecological organs. - **The application of HRT**: HRT is often used to improve menopausal symptoms, but its impact on the malignant transformation of endometriosis is not clear. - **Limitations of existing research**: Currently, the quality of research on the impact of HRT on the recurrence and malignant transformation of endometriosis is low, and there is a lack of high - quality evidence. ### Research methods: - **Data sources**: Use the data of the Korea Health Insurance Review and Assessment Service (HIRA). - **Research objects**: Select women diagnosed with endometriosis between 2007 and 2022, and divide them into the HRT group and the control group. - **Matching criteria**: Match 1:1 according to the age of the last visit. - **Exclusion criteria**: Exclude women aged 49 and below, women who had cancer within one year before or after the diagnosis of endometriosis, etc. ### Research results: - **Overall cancer incidence**: In both the HRT group and the control group, the incidence of various cancers is very low (0.2% to 1.5%). - **The impact of HRT on uterine cancer**: HRT significantly increases the risk of uterine cancer (p < 0.05). - **The impact of HRT on other cancers**: - **Liver cancer**: The longer the HRT is used, the significantly lower the risk of liver cancer (p < 0.05). - **Combined use of estrogen and progesterone**: Significantly reduces the risk of liver cancer and thyroid cancer (p < 0.05). - **Use of estrogen alone**: Significantly reduces the risk of breast cancer and lung cancer (p < 0.05). - **Tibolone**: No association with any cancer risk has been found. ### Conclusions: - **The risk of HRT on uterine cancer**: HRT significantly increases the risk of uterine cancer. - **The impact of different types of HRT**: The combined use of estrogen and progesterone can reduce the risk of liver cancer and thyroid cancer, while the use of estrogen alone can reduce the risk of breast cancer and lung cancer. - **The safety of tibolone**: Tibolone has no relation to any cancer risk. These results provide important guiding information for post - menopausal women with new - onset or a history of endometriosis using HRT.

Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis